GenOdyssee

GenOdyssee was a biotechnology company focused on the discovery and development of next-generation therapeutic proteins, specifically within the interferon family. The company utilized a proprietary platform that leveraged natural human genetic diversity to identify cytokine variants with superior efficacy and reduced toxicity compared to standard treatments. Its lead program, GE-101, was a novel interferon alpha variant developed for the treatment of chronic Hepatitis C. By focusing on naturally occurring genetic variations (SNPs), GenOdyssee aimed to develop "bio-better" versions of established biologics. The company's approach was rooted in the belief that evolutionary selection provides a roadmap for optimized protein sequences.